1. Home
  2. QCLS vs RVPH Comparison

QCLS vs RVPH Comparison

Compare QCLS & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

QCLS

Q/C Technologies Inc.

N/A

Current Price

$4.08

Market Cap

27.6M

Sector

Health Care

ML Signal

N/A

Logo Reviva Pharmaceuticals Holdings Inc.

RVPH

Reviva Pharmaceuticals Holdings Inc.

N/A

Current Price

$2.88

Market Cap

29.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
QCLS
RVPH
Founded
2014
2006
Country
United States
United States
Employees
2
14
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.6M
29.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
QCLS
RVPH
Price
$4.08
$2.88
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$3.33
AVG Volume (30 Days)
836.6K
3.0M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.50
$0.17
52 Week High
$8.17
$1.23

Technical Indicators

Market Signals
Indicator
QCLS
RVPH
Relative Strength Index (RSI) 51.70 95.27
Support Level $4.00 $0.34
Resistance Level $4.57 N/A
Average True Range (ATR) 0.38 0.04
MACD 0.07 0.17
Stochastic Oscillator 42.77 93.20

Price Performance

Historical Comparison
QCLS
RVPH

About QCLS Q/C Technologies Inc.

Q/C Technologies Inc is engaged in building blockchain infrastructure that is faster and more energy-efficient. The company uses laser-based processors inspired by quantum technology that can solve complex problems at the speed of light. By combining photonic computing with cryptocurrency systems, the company creates powerful and sustainable solutions for the next generation of blockchain applications.

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.

Share on Social Networks: